Dr. Hyun Sook Park | Medicine and Dentistry | Women Researcher Award

CEO at CEFO, South Korea

Dr. Hyun-Sook Park is an accomplished researcher and leader in the fields of stem cell science, tissue engineering, and regenerative medicine. She holds a Ph.D. in Pathology from Imperial College London, where she focused on adult stem cells in the gastrointestinal tract. As the CEO of CEFO Bio Co., Ltd, Dr. Park has spearheaded innovations in stem cell therapies and bioengineering, with significant contributions to skin regeneration and pancreatic beta-cell differentiation. Her academic career includes roles as an affiliated professor at prestigious Korean universities. Dr. Park has held key leadership positions, including serving on boards for the Korea Society of Stem Cell Research and the Korean Tissue Engineering & Regenerative Medicine. She has received numerous awards, such as the British Council Ph.D. Award and Digital Innovation Award, recognizing her groundbreaking research. Dr. Park is also actively involved in shaping national policy on biomedical sciences and advancing global research initiatives.

Professional Profile

• Scopus Profile

Education

Dr. Hyun-Sook Park has a distinguished academic background, with degrees from prestigious institutions. She earned her Bachelor of Science in Biology from Korea University in Seoul (1982-1986), followed by a Master of Science in Zoology from the same university (1986-1988). Dr. Park then pursued a Ph.D. in Pathology at Imperial College London, where she focused on adult stem cells in the gastrointestinal tract and their role in cancer development and regeneration. She completed her Ph.D. under the supervision of Dr. Nicholas A. Wright in 1997, at the Imperial College School of Medicine. Her research at Imperial College, specifically on gastrointestinal epithelial stem cells, marked the beginning of her long-standing interest in stem cell science. This educational foundation laid the groundwork for her future groundbreaking contributions to stem cell research, tissue engineering, and regenerative medicine, establishing her as a leader in the biomedical field.

Professional Experience

Dr. Hyun-Sook Park has an extensive professional career in biomedical research and leadership. She is the CEO of CEFO Bio Co., Ltd, where she oversees the company’s innovative work in stem cell therapies and bioengineering. Dr. Park’s research experience spans several prestigious institutions. She served as Vice Director at BioSolution (2007-2011), focusing on human embryonic stem cells and skin regeneration. Prior to this, she was Director of the Research Institute at MizMedi Hospital Medical Research Center (2005-2007), where she studied stem cell differentiation. Dr. Park also worked as a Senior Research Scientist at the Institute of Radiological and Medical Sciences (1999-2005), specializing in tissue engineering and pancreatic beta-cell differentiation. She has held postdoctoral roles, including at the Korea Research Institute of Bioscience and Biotechnology, and was a visiting researcher at the Imperial Cancer Research Fund. Her career has also included advisory roles and leadership in scientific committees and organizations.

Research Interests

Dr. Hyun-Sook Park’s research interests are centered around stem cell science, tissue engineering, and regenerative medicine. Her early work focused on adult stem cells in the gastrointestinal tract, exploring their role in cancer development and tissue regeneration. Over the years, she expanded her research to encompass a range of biomedical applications, including human embryonic stem cell differentiation, specifically in endodermal and mesodermal lineages. Dr. Park has made significant contributions to the development of bioartificial tissues, such as skin regeneration, and the differentiation of pancreatic beta cells from stem cells for potential diabetes treatments. Her research also explores gene therapy and the use of stem cells in cancer therapies. More recently, she has been involved in advanced techniques, such as the use of ultra-sensitive nanoparticles for tracking endothelial cells. Dr. Park’s work is crucial in advancing regenerative medicine and tissue engineering, with the potential to revolutionize treatments for various diseases.

Awards and Honors

Dr. Hyun-Sook Park has received numerous prestigious awards and honors throughout her career, recognizing her exceptional contributions to scientific research and innovation. Among her accolades is the British Council Ph.D. Award (1990) for her outstanding academic achievements. She also received the Digital Innovation Award in 2014 and 2017, acknowledging her pioneering work in stem cell research and regenerative medicine. Dr. Park was awarded the Overseas Research Scholarship Award (1990-1993) and the Weston Scholarship in the Royal Postgraduate Medical School (1990-1993), which supported her studies at Imperial College London. In addition to these awards, Dr. Park’s research has been consistently recognized by the scientific community, reflected in her extensive publication record and involvement in high-impact projects. Her leadership in the field is further highlighted by her membership in influential committees and advisory roles, shaping national policies in biomedical research. These honors underscore her significant impact on science and healthcare advancements.

Conclusion

Dr. Hyun-Sook Park is an outstanding candidate for the Women Researcher Award. With her exemplary leadership in bioengineering and stem cell research, she has made tremendous contributions to the scientific community. Her innovations in regenerative medicine and cancer research, along with her leadership in key professional and governmental committees, underline her profound impact on both science and policy. While there are opportunities for her to increase her global visibility and outreach, her achievements clearly demonstrate the caliber of a distinguished researcher deserving of this prestigious award.

Publications Top Noted

• Evaluation of Safety and Efficacy of Cell Therapy Based on Osteoblasts Derived from Umbilical Cord Mesenchymal Stem Cells for Osteonecrosis of the Femoral Head: Study Protocol for a Single-Center, Open-Label, Phase I Clinical Trial
  • Authors: Baek, S.-H., Shim, B.-J., Won, H., Park, H.S., Kim, S.-Y.
  • Year: 2024
  • Citations: 0
• Early Osteogenic-Induced Adipose-Derived Stem Cells and Canine Bone Regeneration Potential Analyzed Using Biodegradable Scaffolds
  • Authors: Yun, H.-H., Kim, S.-G., Park, S.-I., Hong, I.-H., Jeong, K.-S.
  • Year: 2023
  • Citations: 2
• In Vitro Tracking of Human Umbilical Vein Endothelial Cells Using Ultra-Sensitive Quantum Dot-Embedded Silica Nanoparticles
  • Authors: Kim, J., Lee, S., Lee, Y.K., Jun, B.-H., Park, H.-S.
  • Year: 2023
  • Citations: 6
• Comparison of Temperature Equilibrium Rate and Cell Growth/Viability Under Air Circulation in Cryogenic Storage Container
  • Authors: Park, J.-Y., Lee, D.-W., Lee, S., Park, H.-S., Yoon, G.-S.
  • Year: 2022
  • Citations: 0
• Medroxyprogesterone Reverses Tolerable Dose Metformin-Induced Inhibition of Invasion via Matrix Metallopeptidase-9 and Transforming Growth Factor-β1 in KLE Endometrial Cancer Cells
  • Authors: Suh, D.H., Lee, S., Park, H.-S., Park, N.H.
  • Year: 2020
  • Citations: 4
• Differentiation of Equine Induced Pluripotent Stem Cells into Mesenchymal Lineage for Therapeutic Use
  • Authors: Chung, M.-J., Park, S., Son, J.-Y., Park, H.-S., Jeong, K.-S.
  • Year: 2019
  • Citations: 19
• Establishment of Stably Expandable Induced Myogenic Stem Cells by Four Transcription Factors
  • Authors: Lee, E.-J., Kim, M., Kim, Y.D., Hwang, D., Jeong, K.-S.
  • Year: 2018
  • Citations: 15
• Recurrent Variations in DNA Methylation in Human Pluripotent Stem Cells and Their Differentiated Derivatives
  • Authors: Nazor, K.L., Altun, G., Lynch, C., Loring, J.F., Laurent, L.C.
  • Year: 2012
  • Citations: 316
• The Effects of the Physical Properties of Culture Substrates on the Growth and Differentiation of Human Embryonic Stem Cells
  • Authors: Lee, S., Kim, J., Park, T.J., Kang, S., Park, H.-S.
  • Year: 2011
  • Citations: 29
• Comparison of Mesenchymal-like Stem/Progenitor Cells Derived from Supernumerary Teeth with Stem Cells from Human Exfoliated Deciduous Teeth
  • Authors: Lee, S., An, S., Kang, T.H., Kwak, C.K., Park, H.-S.
  • Year: 2011
  • Citations: 29

Dr. Pengyi Liu | Medicine and Dentistry | Best Researcher Award

Doctoral student at Shanghai Ruijin Hospital, China

Dr. Pengyi Liu is a dedicated researcher specializing in the tumor immune microenvironment of pancreatic cancer. Currently pursuing a doctoral degree at Ruijin Hospital, Shanghai Jiaotong University, Liu’s work focuses on understanding the roles of macrophages and T cells in tumor progression. With a Bachelor’s degree in Clinical Medicine, Liu has consistently excelled academically, earning numerous honors, including multiple scholarships and recognition as an “Outstanding Graduate.” Their research has led to significant publications in high-impact journals, exploring novel mechanisms in pancreatic cancer, such as macrophage differentiation and immune response modulation. Proficient in various experimental techniques like cell culture, flow cytometry, and molecular biology, Liu demonstrates a broad skill set essential for cutting-edge cancer research. Their collaborative efforts and innovative approaches continue to advance the field, offering potential new targets for diagnosis and treatment. Liu’s work holds promise for improving clinical outcomes in pancreatic cancer patients.

Professional Profile

• Scopus Profile

Education

Dr. Pengyi Liu’s educational journey reflects a strong foundation in clinical medicine and research. He completed his Bachelor’s degree in Clinical Medicine at Shanghai Jiaotong University from 2016 to 2021, achieving a commendable GPA of 3.63. During this time, Liu was recognized for his academic excellence, earning multiple scholarships and being named a “Merit Student” in 2020. After completing his undergraduate studies, Liu continued his education at Ruijin Hospital, affiliated with Shanghai Jiaotong University School of Medicine, where he is currently pursuing a Doctor of Surgery degree under the prestigious “Zhiyuan Honors Program.” His research is guided by Prof. Baiyong Shen, focusing on the molecular mechanisms of pancreatic cancer. In addition to his rigorous academic training, Liu has taken a wide range of courses, including Anatomy, Physiology, Molecular Biology, Immunology, and Laboratory Animal Science, providing him with a well-rounded knowledge base for his advanced research.

Professional Experience

Dr. Pengyi Liu’s professional experience is centered around groundbreaking research in the field of pancreatic cancer. Currently a doctoral candidate at Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Liu is engaged in advanced research on the tumor immune microenvironment, particularly the roles of macrophages and T cells in tumor progression. Under the mentorship of Prof. Baiyong Shen, Liu has contributed to numerous high-impact publications on pancreatic cancer, including studies on macrophage differentiation, immune modulation, and tumor progression. His research projects are multifaceted, encompassing both molecular and animal model-based approaches to uncover novel mechanisms and potential therapeutic targets. Liu is proficient in various laboratory techniques, including cell culture, flow cytometry, molecular biology assays, and the construction of patient-derived xenograft and organoid models. His work continues to shape the understanding of pancreatic cancer, offering new insights into its diagnosis, treatment, and the development of targeted therapies.

Research Interests

Dr. Pengyi Liu’s research interests are centered around the tumor immune microenvironment, with a particular focus on pancreatic cancer. His work aims to understand the complex interactions between immune cells, such as macrophages and T cells, and tumor progression. Liu is dedicated to uncovering the molecular mechanisms that drive pancreatic cancer, especially how immune cells contribute to the tumor environment and influence cancer growth. His research explores the roles of various molecules, including lncRNAs and signaling pathways, in shaping the immune response and tumor microenvironment. By studying the molecular and cellular processes in pancreatic cancer, Liu aims to identify potential therapeutic targets for better diagnosis and treatment strategies. Additionally, Liu’s work involves the development and use of advanced experimental models, such as patient-derived xenografts and organoids, to simulate the tumor environment and test new treatment approaches. His goal is to bridge the gap between basic research and clinical application in oncology.

Awards and Honors

Dr. Pengyi Liu has received numerous awards and honors throughout his academic career, reflecting his exceptional performance and dedication to research. He was awarded the prestigious scholarships of Shanghai Jiaotong University in 2017, 2018, 2019, and 2020, which recognize his academic excellence. In 2020, he was named a “Merit Student,” further highlighting his outstanding achievements. Dr. Liu’s dedication to his studies was also acknowledged when he was recognized as an “Outstanding Graduate” in 2021, a testament to his strong academic record and research contributions. Additionally, as a graduate student, he was awarded the First-Class Scholarship in 2022 and the Second-Class Scholarship in 2023, underscoring his continued academic excellence and research productivity. These accolades demonstrate not only his commitment to excellence but also the recognition he has earned from his peers and academic community for his hard work and significant contributions to the field of medical research.

Conclusion

Pengyi Liu’s academic achievements, extensive research experience, and significant contributions to understanding the tumor immune microenvironment in pancreatic cancer make them a strong contender for the Best Researcher Award. With a clear focus on advancing scientific knowledge and potential for real-world impact, Liu exemplifies the qualities of a leading researcher. Continued diversification of their research scope and greater emphasis on clinical applications could further amplify their contributions to the field.

Publications Top Noted

1. Comprehensive analysis of KLF family reveals KLF6 as a promising prognostic and immune biomarker in pancreatic ductal adenocarcinoma
   • Authors: Lin, J., Liu, P., Sun, K., Wang, T., Shen, B.
   • Year: 2024
   • Journal: Cancer Cell International
   • Citations: 0
2. Pan-cancer analysis implicates novel insights of lactate metabolism into immunotherapy response prediction and survival prognostication
   • Authors: Chen, D., Liu, P., Lu, X., Li, H., Shen, B.
   • Year: 2024
   • Journal: Journal of Experimental and Clinical Cancer Research
   • Citations: 0
3. ATF3-induced activation of NF-κB pathway results in acquired PARP inhibitor resistance in pancreatic adenocarcinoma
   • Authors: Liu, Y., Cao, Y., Liu, P., Wang, W., Shen, B.
   • Year: 2024
   • Journal: Cellular Oncology
   • Citations: 2
4. BHLHE40 Inhibits Ferroptosis in Pancreatic Cancer Cells via Upregulating SREBF1
   • Authors: Cao, Y., Wang, X., Liu, Y., Jiang, L., Shen, B.
   • Year: 2024
   • Journal: Advanced Science
   • Citations: 3
5. CTCF enhances pancreatic cancer progression via FLG-AS1-dependent epigenetic regulation and macrophage polarization
   • Authors: Liu, Y., Liu, P., Duan, S., Jiang, Y., Shen, B.
   • Year: 2024
   • Journal: Cell Death and Differentiation
   • Citations: 0
6. SNHG17 alters anaerobic glycolysis by resetting phosphorylation modification of PGK1 to foster pro-tumor macrophage formation in pancreatic ductal adenocarcinoma
   • Authors: Lin, J., Liu, Y., Liu, P., Bao, H., Lin, J.
   • Year: 2023
   • Journal: Journal of Experimental and Clinical Cancer Research
   • Citations: 0
7. A microprotein N1DARP encoded by LINC00261 promotes Notch1 intracellular domain (N1ICD) degradation via disrupting USP10-N1ICD interaction to inhibit chemoresistance in Notch1-hyperactivated pancreatic cancer
   • Authors: Zhai, S., Lin, J., Ji, Y., Deng, X., Shen, B.
   • Year: 2023
   • Journal: Cell Discovery
   • Citations: 10
8. Single-cell RNA-seq analysis reveals BHLHE40-driven pro-tumour neutrophils with hyperactivated glycolysis in pancreatic tumour microenvironment
   • Authors: Wang, L., Liu, Y., Dai, Y., Chen, S., Shen, B.
   • Year: 2023
   • Journal: Gut
   • Citations: 100
9. LncRNA-PACERR induces pro-tumour macrophages via interacting with miR-671-3p and m6A-reader IGF2BP2 in pancreatic ductal adenocarcinoma
   • Authors: Liu, Y., Shi, M., He, X., Sun, B., Shen, B.
   • Year: 2022
   • Journal: Journal of Hematology and Oncology
   • Citations: 76

Dr. Tingting Gao | Medicine and Dentistry | Best Researcher Award

Doctor at Shanxi medical university, China

Dr. Tingting Gao is a dedicated and accomplished medical researcher with a strong focus on vascular surgery, immunometabolomics, and multimodal molecular imaging. She is currently pursuing her Doctor of Medicine and Master of Medicine at Shanxi Medical University, where she works under the guidance of Professor Honglin Dong. With a broad range of research interests and expertise in cutting-edge imaging technologies, Dr. Gao has made significant contributions to the understanding of vascular diseases, atherosclerosis, and kidney injury. Her work bridges the gap between experimental biology and clinical applications, demonstrating a commitment to advancing both basic and translational research.

Professional Profile

• Scopus Profile

Education

Dr. Tingting Gao is currently completing her Doctor of Medicine and Master of Medicine at Shanxi Medical University, Taiyuan, China. She has been under the academic mentorship of Dr. Honglin Dong, MD, Ph.D., Assistant Dean of The Second Hospital of Shanxi Medical University. Her education has provided her with a strong foundation in both medical practice and research, allowing her to contribute to the field of vascular surgery while pursuing advanced studies in molecular medicine and disease mechanisms. Her educational journey emphasizes her dedication to both scientific inquiry and clinical expertise.

Professional Experience

Dr. Gao’s professional experience includes significant roles as a Research Assistant in the Department of Vascular Surgery at The Second Hospital of Shanxi Medical University, where she has worked from 2023 to the present. In this role, she conducts research focused on immunometabolomics and multimodal molecular imaging of vascular diseases. She has also worked as a subject participant in various research projects, such as the study of aortic aneurysms and contrast-induced acute kidney injury. Additionally, Dr. Gao has extensive clinical experience in vascular surgery, having worked from 2018 to 2022 in the same hospital, gaining hands-on expertise in patient care and surgical procedures.

Research Interests

Dr. Gao’s research interests span several domains, including vascular surgery, atherosclerosis, liver disease, and imaging technologies. She is particularly interested in the mechanisms underlying vascular diseases, such as atherosclerosis, and how substances like garlic can impact these conditions. Her work integrates network pharmacology, bioinformatics, and experimental verification to explore therapeutic pathways like ferroptosis. Additionally, she focuses on advanced imaging techniques, such as photoacoustic microscopy and magnetic nanoparticle imaging, to better understand disease mechanisms and improve diagnostic tools. Her multidisciplinary approach blends laboratory research with clinical applications, aiming to make a significant impact in both fields.

Awards and Honors

Dr. Gao has received recognition for her research contributions through various awards and honors. She has been a part of multiple funded projects, including those by the Shanxi Provincial Science and Technology Department and the Scientific and Technological Innovation Programs of Higher Education Institutions in Shanxi Province. These grants have supported her participation in cutting-edge research exploring vascular diseases, kidney injury, and novel imaging technologies. Dr. Gao’s dedication to her field has also been acknowledged by her peers, reflected in her impressive publication record and active participation in international conferences, where she has presented her findings at major forums like the World Molecular Imaging Society.

Conclusion

The individual appears highly deserving of the Best Researcher Award due to their comprehensive academic background, impressive publication record, technical expertise, and contributions to advanced research in vascular diseases, imaging technologies, and pharmacology. They have demonstrated creativity and leadership in scientific exploration, with innovative work that holds significant potential for clinical applications. However, future opportunities for growth could include assuming more independent leadership roles, increasing international recognition, and further advancing the clinical impact of their research.

Publications Top Noted

Assoc. Prof. Dr. Guoping Zheng | Medicine and Dentistry | Best Researcher Award

Laboratory head at University of Sydney (WIMR), Australia

Associate Professor Guoping Zheng is a renowned researcher and academic in the field of medicine, specializing in kidney injury, repair, and fibrosis. He is currently an Associate Professor at the University of Sydney, within the Faculty of Medicine and Health, and holds a prestigious NHMRC Principal Research Fellowship at the Westmead Institute for Medical Research. Dr. Zheng has led pioneering research projects in kidney transplantation, fibrosis, and inflammatory diseases, contributing significantly to our understanding of kidney pathophysiology and potential therapeutic interventions. With a research portfolio that spans over two decades, Dr. Zheng has garnered international recognition for his innovative work in renal medicine, including developing engineered macrophages for treating chronic kidney disease. His research impact is further demonstrated by his high citation index, editorial roles in top journals, and his numerous academic and institutional leadership positions.

Professional Profile

• Scopus Profile
• ORCID Profile
• Googel Scholar

Education

Dr. Guoping Zheng has an impressive educational background in medical and molecular sciences. He earned his PhD from the University of Sydney’s Faculty of Medicine, where he conducted research from 1998 to 2002. Before that, he completed a Master of Medicine by research at Shanxi Medical University in China, specializing in biochemistry and molecular biology from 1985 to 1988. Dr. Zheng also holds an MBBS degree from the same institution, completed in 1985. His educational journey laid a strong foundation for his future research and teaching career, enabling him to contribute extensively to the understanding of kidney disease, renal fibrosis, and related inflammatory processes.

Professional Experience

Dr. Zheng has held a distinguished academic career, with extensive roles at the University of Sydney and the Westmead Institute for Medical Research (WIMR). Since 2003, he has been a key figure at the Centre for Transplantation and Renal Research, where he currently serves as an Associate Professor and leads the Kidney Injury Repair and Fibrosis Study Group. His prior roles include Senior Research Officer and Research Officer, with a focus on kidney pathology. Dr. Zheng has also been an NHMRC Peter Doherty Fellow and a lecturer at the University of Sydney. His professional trajectory reflects a deep commitment to advancing medical research and education, particularly in the field of nephrology and renal transplantation. Additionally, Dr. Zheng has held several executive committee positions at WIMR and serves as a mentor and reviewer for multiple research bodies and academic institutions globally.

Research Interests

Dr. Zheng’s research focuses on kidney injury, repair mechanisms, and fibrosis, particularly in the context of chronic kidney disease and renal transplantation. His work aims to uncover novel therapeutic strategies for kidney fibrosis, a key driver of kidney failure. Dr. Zheng has explored several molecular pathways, including the role of macrophages, TGF-β signaling, and matrix metalloproteinases in fibrosis and inflammation. His research also investigates the potential of engineered cells, such as chimeric antigen receptor macrophages, to prevent kidney damage. Another significant area of interest includes the differentiation of pro-fibrotic from anti-inflammatory effects of TGF-β in kidney fibrosis, which may lead to more effective treatments for renal diseases. Dr. Zheng’s interdisciplinary approach bridges biochemistry, molecular biology, and clinical medicine, advancing both basic science and therapeutic innovation in renal health.

Awards and Honors

Dr. Zheng has received numerous awards and honors throughout his distinguished career, recognizing his outstanding contributions to medical research. He has been awarded the prestigious Westmead Millennium Institute Science Prize five times (2006, 2010, 2013, 2017, and 2021), which is granted to the best original research within his institution. Additionally, he was a finalist for the Basic Science Award at both the 55th ANZSN Annual Scientific Meeting (2020) and the 5th Asian Pacific Congress of Nephrology (2016). Dr. Zheng has also received various recognitions for his poster presentations and research symposia, including multiple “Best Poster Presentation Prizes” at the Annual Research Symposium during Hospital Week. These honors reflect his ongoing dedication to advancing scientific understanding in nephrology and transplantation. Moreover, he has been recognized internationally with travel awards and fellowships, including the New Investigator Travel Award for the Pan-Pacific Connective Tissue Societies Symposium in 1999.

Conclusion

Associate Professor Guoping Zheng stands as a highly suitable candidate for the Best Researcher Award. His extensive research experience, influential publications, multiple awards, and leadership in renal medicine demonstrate a strong commitment to advancing medical knowledge and treatment options for kidney disease. Areas of further development, such as advancing his work’s clinical translation and expanding international collaborations, could add even more depth to his already impressive career. Overall, Dr. Zheng’s accomplishments, recognized expertise, and continuous contributions make him a deserving candidate for this prestigious recognition.

Publications Top Noted